FDA AdComm Meeting for NurOwn's ALS Therapy Is Critical.

Published Date: 06 Apr 2023

Natalia A. The phase 3 NurOwn pivotal trial's principal investigator, Goyal, MD, spoke about the significance of the upcoming FDA AdComm meeting and its effects on the ALS community.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot